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A bs tr ac t
Background
The use of n–3 fatty acids may prevent cardiovascular events in patients with recent 
myocardial infarction or heart failure. Their effects in patients with (or at risk for) 
type 2 diabetes mellitus are unknown.
Methods
In this double-blind study with a 2-by-2 factorial design, we randomly assigned 
12,536 patients who were at high risk for cardiovascular events and had impaired 
fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule 
containing at least 900 mg (90% or more) of ethyl esters of n–3 fatty acids or pla-
cebo daily and to receive either insulin glargine or standard care. The primary 
outcome was death from cardiovascular causes. The results of the comparison be-
tween n–3 fatty acids and placebo are reported here.
Results
During a median follow up of 6.2 years, the incidence of the primary outcome was 
not significantly decreased among patients receiving n–3 fatty acids, as compared 
with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard 
ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P = 0.72). The use of n–3 fatty 
acids also had no significant effect on the rates of major vascular events (1034 pa-
tients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; 
P = 0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% 
CI, 0.89 to 1.07; P = 0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; 
hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P = 0.26). Triglyceride levels were reduced by 
14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n–3 fatty 
acids than among those receiving placebo (P<0.001), without a significant effect on 
other lipids. Adverse effects were similar in the two groups.
Conclusions
Daily supplementation with 1 g of n–3 fatty acids did not reduce the rate of cardio-
vascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; 
ORIGIN ClinicalTrials.gov number, NCT00069784.)
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The use of n–3 fatty acids may have beneficial effects on arrhythmias, elevated triglyceride levels, atherosclerotic plaque, 
impaired endothelial function, platelet aggrega-
tion, and inflammation. Epidemiologic studies 
have shown a reduced risk of cardiovascular 
events among persons who consume fish regularly 
or who take supplements containing n–3 fatty 
acids.1-4 These data have provided the impetus 
for clinical trials evaluating the effect of such 
supplements on cardiovascular events and death. 
These studies included participants with a variety 
of cardiovascular risk factors, were either open-
label or placebo-controlled, and tested either di-
etary regimens or pharmaceutical preparations 
containing n–3 fatty acids. Previous meta-analy-
ses of such trials of n–3 fatty acids have shown 
modest reductions in the rates of fatal and non-
fatal cardiovascular events.5-7 However, a recent 
meta-analysis that was limited to blinded, ran-
domized, placebo-controlled trials of such sup-
plementation showed no effect on cardiovascular 
outcomes.8
Patients with type 2 diabetes, impaired fast-
ing glucose, or impaired glucose tolerance are at 
increased risk for cardiovascular events,9 but no 
large trials have focused on the effect of n–3 fatty 
acids in such patients. In the Outcome Reduc-
tion with Initial Glargine Intervention (ORIGIN) 
trial,10 we tested the hypothesis that long-term 
supplementation with n–3 fatty acids would re-
duce the rate of cardiovascular events in this 
population of patients.
Me thods
Study Design
In a randomized trial with a 2-by-2 factorial de-
sign, we sought to determine the effect of a 1-g 
capsule containing at least 900 mg (90% or more) 
of ethyl esters of n–3 fatty acids (Omacor, Prono-
va BioPharma Norge) as compared with placebo 
and of insulin glargine as compared with stan-
dard care on cardiovascular outcomes in patients 
with (or at risk for) diabetes. Details regarding 
the design of this study were published in 2008,10 
and the results of the insulin glargine interven-
tion are reported separately in the Journal by Ger-
stein et al.11 The study protocol is provided with 
the full text of this article at NEJM.org. The ethics 
committee at each participating site approved the 
trial, and all participants provided written in-
formed consent.
Participants
Eligibility criteria were an age of at least 50 years; 
a diagnosis of diabetes with receipt of no more 
than one oral glucose-lowering drug, impaired 
glucose tolerance (plasma glucose level at 2 hours, 
≥7.8 mM [140 mg per deciliter] and <11.1 mM 
[200 mg per deciliter] after a 75-g oral glucose 
load), or impaired fasting glucose (range, ≥6.1 mM 
[110 mg per deciliter] to <7.0 mM [126 mg per 
deciliter]); a history of myocardial infarction, 
stroke, or revascularization; angina with docu-
mented ischemia; a ratio of urinary albumin to 
creatinine of more than 30 mg per gram; left 
ventricular hypertrophy; 50% or more stenosis of 
a coronary, carotid, or lower-limb artery on angiog-
raphy; or an ankle–brachial index of less than 0.9.
Participants were excluded if they were un-
willing to discontinue use of a nonstudy prepa-
ration of n–3 fatty acids, had a locally measured 
glycated hemoglobin level of 9% or more, had 
undergone coronary-artery bypass grafting with-
in the previous 4 years with no intervening car-
diovascular event, had severe heart failure, or had 
a cancer that might affect survival.
Randomization, Study Intervention,  
and Follow-up
Participants underwent randomization, after a 
10-day run-in period, to receive either 1 g of n–3 
fatty acids (containing 465 mg of eicosapentae-
noic acid [EPA] and 375 mg of docosahexaenoic 
acid [DHA]) or placebo containing approximately 
1 g of olive oil.
We evaluated clinical outcomes occurring after 
randomization, adherence to the study-drug regi-
men, and adverse events associated with a change 
in the dose of a study drug during follow-up visits 
at 0.5, 1, 2, and 4 months after randomization 
and every 4 months thereafter. We made no study-
specific dietary recommendations pertaining to 
consumption of fish or other marine products. 
However, the use of nonstudy supplements con-
taining n–3 fatty acids was discouraged. A food-
frequency questionnaire was administered at ran-
domization, at 2 years, and at the end of the study. 
We calculated the dietary intake of EPA and DHA 
at baseline, at 2 years, and at the end of the study, 
using data from the food-frequency questionnaire 
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and the Department of Agriculture National Nu-
trient Database for Standard Reference, release 23 
(USDA Food Search for Windows, version 1.0).
Study Outcomes
The primary outcome was death from cardiovas-
cular causes. Secondary outcomes included the 
composite outcome of death from cardiovascular 
causes, nonfatal myocardial infarction, or nonfa-
tal stroke; death from any cause; and death from 
arrhythmia (which included sudden unexpected 
death, death from documented arrhythmia, un-
witnessed death, and resuscitated cardiac arrest). 
Other outcomes included all myocardial infarc-
tions, all strokes, revascularizations, heart fail-
ure, angina, limb amputation for ischemia, and 
hospitalization for cardiovascular causes. All pri-
mary and secondary outcomes were adjudicated 
with the use of prespecified definitions by a 
committee whose members were unaware of 
12,611 Underwent randomization
13,765 Were included in run-in
1154 Were excluded
356 Had ineligible plasma glucose
42 Were ineligible for other reasons
397 Were nonadherent in run-in
264 Withdrew consent
95 Had other reasons
15,392 Patients were assessed for eligibility
1627 Were excluded
322 Did not meet inclusion criteria
10 Declined to participate
1295 Had other reasons
6319 Were assigned to receive n–3 fatty acids 6292 Were assigned to receive placebo
38 Were excluded by health
authorities in countries
with study centers
37 Were excluded by health
authorities in countries
with study centers
6281 Were included in the analysis 6255 Were included in the analysis
6220 Had known outcome status
61 Did not have final outcome status
14 Withdrew consent
38 Did not give consent to extension
9 Were lost to follow-up
6208 Had known outcome status
47 Did not have final outcome status
18 Withdrew consent
20 Did not give consent to extension
9 Were lost to follow-up
Figure 1. Enrollment and Outcomes.
One participant who underwent randomization in the glucose-lowering portion of the study died before randomi-
zation to n–3 fatty acids or placebo. Data for 38 patients in the group receiving n–3 fatty acids and for 37 patients in 
the placebo group were excluded at the request of health authorities after site audits.
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study-group assignments. Detailed definitions of 
key study outcomes are in the Supplementary Ap-
pendix, available at NEJM.org.
Study Oversight
The trial was designed and conducted by the steer-
ing committee, which included the two principal 
investigators, national leaders from each partici-
pating country, one representative from the man-
ufacturer of n–3 fatty acids (Pronova BioPharma 
Norge), and one representative from the trial 
sponsor (Sanofi, which manufactures insulin 
glargine). Project management, data manage-
ment, support for the adjudication committee, 
and statistical analyses were all independently 
provided by the trial’s project office, based at the 
Population Health Research Institute in Hamil-
ton, Ontario, Canada. An independent data and 
safety monitoring committee reviewed efficacy 
and safety outcomes on a regular basis. Two 
planned interim analyses were conducted when 
50% and 75% of the expected number of events 
had occurred. Funding and regulatory support 
were provided by Sanofi. Capsules containing 
n–3 fatty acids and placebo were provided by Pro-
nova BioPharma Norge. The steering committee 
prepared the manuscript, made the decision to 
submit it for publication, and vouches for the 
completeness and accuracy of the data and the 
fidelity of the study to the protocol.
Statistical Analysis
We calculated that the enrollment of 12,500 par-
ticipants during a 2-year period, with follow-up 
for at least 6 years, would provide a power of 90% 
to detect an 18.6% reduction (and a power of 80% 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
n–3 Fatty Acids  
(N = 6281)
Placebo
(N = 6255)
Age — yr 63.5±7.8 63.6±7.9
Female sex — no. (%) 2176 (34.6) 2210 (35.3)
Cardiovascular history or risk factors — no. (%)
Myocardial infarction, stroke, or revascularization 3713 (59.1) 3664 (58.6)
Hypertension 4941 (78.7) 5021 (80.3)
Current smoking 762 (12.1) 790 (12.6)
Other risk factors — no. (%)
Microalbuminuria or macroalbuminuria 980 (15.6) 944 (15.1)
History of cancer 279 (4.4) 274 (4.4)
Body-mass index† 29.8±5.3 29.9±5.2
Heart rate — beats per minute 69.9±12.2 69.8±12.1
Blood pressure — mm Hg
Systolic 145.6±21.8 146.0±21.8
Diastolic 84.1±12.1 84.2±12.1
Ankle–brachial index 1.16±0.21 1.16±0.20
Cholesterol — mg/dl
Total 189±46 190±47
Low-density lipoprotein 112±40 112±40
High-density lipoprotein 46±12 46±12
Serum creatinine — mg/dl 1.0±0.3 1.0±0.2
Estimated glomerular filtration rate — ml/min/1.73 m2 77.1±21.5 77.5±21.1
Fasting plasma glucose — mg/dl
Median 125 124
Interquartile range 110–148 108–148
Glycated hemoglobin — %
Median 6.4 6.4
Interquartile range 5.8–7.2 5.8–7.2
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to detect a 16.4% reduction) in the risk of death 
from cardiovascular causes in the group receiv-
ing supplementation with n–3 fatty acids, assum-
ing an event rate of 1.5% per year in the placebo 
group and a two-sided type I error rate of 5%.
To compare the time-to-first-event curves, we 
used an intention-to-treat approach for all effi-
cacy analyses and a log-rank test stratified ac-
cording to the assignment to receive either insu-
lin glargine or standard care, baseline metabolic 
status (impaired fasting glucose, impaired glu-
cose tolerance, newly diagnosed diabetes, or es-
tablished diabetes), and status with respect to a 
history of cardiovascular disease. Estimates of 
the hazard ratios and two-sided 95% confidence 
intervals were calculated overall and for sub-
groups with the use of a Cox regression model 
stratified according to use of insulin glargine 
versus standard care, baseline metabolic status 
(impaired fasting glucose, impaired glucose tol-
erance, newly diagnosed diabetes, or established 
diabetes), and status with respect to a history of 
cardiovascular disease. Cox regression models 
with adjustment for these three factors were used 
if there were fewer than five events in any stra-
tum. For all outcomes and interaction terms, a 
P value of less than 0.05 was considered to in-
dicate statistical significance.
We used the Kaplan–Meier method to create 
survival curves for up to 7 years. We used the 
Peto–Yusuf method to calculate odds ratios and 
confidence intervals for the addition of the 
ORIGIN results to a meta-analysis of the effi-
cacy of n–3 fatty acid supplementation in the 
secondary prevention of cardiovascular disease 
(see the Discussion section).
R esult s
Patients
From September 2003 through December 2005, 
we randomly assigned 12,611 patients to a study 
group. We subsequently excluded data for 75 pa-
tients at the request of national regulatory agen-
cies after local audits. We followed the remaining 
12,536 patients (mean age, 64 years; 35% wom-
Table 1. (Continued.)
Characteristic
n–3 Fatty Acids  
(N = 6281)
Placebo
(N = 6255)
Albumin:creatinine ratio‡
Median 5.2 5.1
Interquartile range 2.5–19.3 2.5–18.1
Triglycerides — mg/dl
Median 142 140
Interquartile range 99–196 97–195
Dietary EPA–DHA intake — mg/day
Median 210.0 209.3
Interquartile range 39.7–577.4 39.6–563.1
Cardiovascular medication — no. (%)
ACE inhibitor or ARB 4320 (68.8) 4360 (69.7)
Thiazide diuretics 1180 (18.8) 1191 (19.0)
Aspirin or other antiplatelet agent 4374 (69.6) 4291 (68.6)
Anticoagulant 438 (7.0) 432 (6.9)
Beta-blocker 3314 (52.8) 3284 (52.5)
Calcium-channel blocker 1708 (27.2) 1751 (28.0)
Statin 3331 (53.0) 3408 (54.5)
* Plus–minus values are means ±SD. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To con-
vert the values for creatinine to micromoles per liter, multiply by 88.4. To convert the values for glucose to millimoles per 
liter, multiply by 0.05551. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. ACE denotes an-
giotensin-converting enzyme, ARB angiotensin-receptor blocker, DHA docosahexaenoic acid, and EPA eicosapentaenoic acid.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Urinary albumin was measured in milligrams, and creatinine was measured in grams.
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en) from 573 centers (cardiology, diabetes, and 
general practice clinics) in 40 countries for a me-
dian of 6.2 years, until November 2011 (Fig. 1). 
At baseline, 59% of the patients had had a myo-
cardial infarction or stroke or had undergone 
revascularization. The median dietary intake of 
EPA or DHA was 210 mg per day (interquartile 
range, 40 to 568) (Table 1). Information regard-
ing the primary outcome was available for 
12,428 patients (99.1%) at the end of the study 
(Fig. 1).
Rates of adherence to the study-drug regimen 
were similar in the two groups, with 96% of pa-
tients continuing to receive a study drug at 1 year, 
92% at 4 years, and 88% at the end of the study. 
Other than participant preference, the most com-
monly reported reasons for permanently stop-
ping a study drug among patients receiving n–3 
fatty acids and those receiving placebo were ab-
dominal discomfort (in 32 patients and 18 pa-
tients, respectively) and lower gastrointestinal 
symptoms (in 14 and 24 patients, respectively). 
Bleeding was reported in 57 patients receiving 
n–3 fatty acids, as compared with 65 patients in 
the placebo group, with intracranial bleeding re-
ported in 42 patients and 51 patients, respectively.
Efficacy Outcomes
Supplementation with n–3 fatty acids did not sig-
nificantly reduce deaths from cardiovascular 
causes, which occurred in 574 patients (9.1%), as 
compared with 581 patients (9.3%) receiving pla-
cebo (hazard ratio, 0.98; 95% confidence interval 
[CI], 0.87 to 1.10; P = 0.72) (Table 2 and Fig. 2). 
There was no significant between-group differ-
ence in the primary outcome in key subgroups, 
including groups defined by baseline consump-
tion of n–3 fatty acids, baseline triglyceride level, 
baseline glycemic status, and assignment to in-
sulin glargine versus standard glycemic treatment 
(Fig. S3 in the Supplementary Appendix). In addi-
tion, the receipt of n–3 fatty acids did not have a 
significant influence on major vascular events, 
which occurred in 1034 patients (16.5%) receiv-
ing n–3 fatty acids, as compared with 1017 pa-
tients (16.3%) receiving placebo (hazard ratio, 
1.01; 95% CI, 0.93 to 1.10; P = 0.81), or on death 
from any cause (951 patients [15.1%] vs. 964 pa-
tients [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 
1.07; P = 0.63), death from arrhythmia (288 [4.6%] 
vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 
1.30; P = 0.26), and all other predefined study 
outcomes (Table 2). There was no significant 
Table 2. Primary and Other Outcomes.
Outcome
n–3 Fatty Acids
(N = 6281)
Placebo
(N = 6255)
Adjusted Hazard 
Ratio (95% CI) P Value
no. (%)
rate/100  
patient-yr no. (%)
rate/100  
patient-yr
Primary outcome: death from cardiovascular causes 574 (9.1) 1.55 581 (9.3) 1.58 0.98 (0.87–1.10) 0.72
Secondary outcomes
Myocardial infarction, stroke, or death from cardio-
vas cular causes
1034 (16.5) 2.92 1017 (16.3) 2.88 1.01 (0.93–1.10) 0.81
Death from any cause 951 (15.1) 2.57 964 (15.4) 2.62 0.98 (0.89–1.07) 0.63
Death from arrhythmia* 288 (4.6) 0.78 259 (4.1) 0.70 1.10 (0.93–1.30) 0.26
Other outcomes
Fatal and nonfatal myocardial infarction 344 (5.5) 0.95 316 (5.1) 0.88 1.09 (0.93–1.27) 0.28
Fatal and nonfatal stroke 314 (5.0) 0.86 336 (5.4) 0.93 0.92 (0.79–1.08) 0.32
Hospitalization for heart failure 331 (5.3) 0.91 320 (5.1) 0.88 1.02 (0.88–1.19) 0.76
Revascularization procedure 866 (13.8) 2.54 896 (14.3) 2.65 0.96 (0.87–1.05) 0.39
Angina† 724 (11.5) 2.11 725 (11.6) 2.12 1.00 (0.90–1.10) 0.94
Limb or digit amputation for ischemia 52 (0.8) 0.14 47 (0.8) 0.13 1.09 (0.74–1.62) 0.67
Hospitalization for any cardiovascular cause 2055 (32.7) 6.87 2087 (33.4) 7.00 0.98 (0.92–1.04) 0.50
* Death from arrhythmia was a composite of sudden unexpected death, nonsudden death, unwitnessed death, or resuscitation after cardiac 
arrest.
† Angina included new, worsening, or unstable disease.
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between-group difference in the rate of cancer 
diagnoses, and there were no significant interac-
tions with the study-group assignments in the 
glucose-lowering portion of the study, indicating 
that the effect was similar for patients in the in-
sulin glargine group and the standard-care group 
(Fig. S3 in the Supplementary Appendix).
By the end of the trial, patients in the group 
receiving n–3 fatty acids had a mean reduction 
in the triglyceride level of 14.5 mg per deciliter 
(0.16 mmol per liter), as compared with the pla-
cebo group (P<0.001) (Table 3). There were no 
other significant between-group differences in 
the levels of other lipid fractions, plasma glucose 
levels, glycated hemoglobin levels, blood pres-
sure, or heart rate (Table 3).
Discussion
In this study, we found that a daily 1-g dose of 
n–3 fatty acids, as compared with placebo, did 
not prevent death or any cardiovascular outcomes 
in patients who had (or were at high risk for) dia-
betes and were at increased risk for cardiovascu-
lar events. Several possibilities may account for 
differences between our findings and the reports 
of benefit from some previous trials of supple-
ments containing n–3 fatty acids.
First, two of the largest trials recruited pa-
tients who had had a myocardial infarction 
within the past 3 months or who had heart fail-
ure.12,13 Such participants might have been more 
likely to benefit from any possible antiarrhyth-
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Figure 2. Primary and Secondary Outcomes.
Shown are the proportions of participants with primary or secondary outcome events. The primary outcome was death from cardiovascular 
causes (Panel A), and the secondary outcomes were a composite of myocardial infarction, stroke, or death from cardiovascular causes 
(Panel B), death from any cause (Panel C), and fatal arrhythmia (Panel D).
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mic effect of n–3 fatty acids than were partici-
pants in our study.
Second, participants in our trial were taking 
more concomitant cardioprotective therapies than 
were those in many previously published trials. 
These therapies may have reduced the incidence 
of death from cardiovascular causes, thereby 
reducing the statistical power to detect any ef-
fect of n–3 fatty acids. These two possibilities 
are supported by the results of a recent trial,14 
which did not show a beneficial effect of n–3 
fatty acids in patients who had had a myocardial 
infarction and were receiving concomitant thera-
pies at proportions similar to those in our study.
Third, participants in some of the other trials 
may have had a daily dietary intake of n–3 fatty 
acids that differed from the intake in our study 
population (median, 210 mg per day) and thus 
might have derived greater benefit from supple-
mentation. Our study did not detect a difference 
in effect on the basis of the dietary intake of n–3 
fatty acids at baseline. However, it should be 
noted that the reported dietary intake of par-
ticipants in our study was well below the 1 g per 
day recommended in various guidelines.15,16
Fourth, our study was restricted to patients 
with impaired fasting glucose, impaired glucose 
tolerance, or diabetes, and n–3 fatty acids may 
not be effective in such patients. However, in 
other trials, analyses of data from participants 
with similar glycemic conditions suggest bene-
fits of supplementation with n–3 fatty acids in 
these subgroups.17,18 Despite these differences, 
the fact that the confidence intervals that were 
observed in our trial clearly overlapped with 
those observed in meta-analyses of the previous 
trials6,8 suggests that our findings are consis-
tent with the small or neutral effect reported in 
these meta-analyses. When the results of our 
study are added to the most recent meta-analy-
sis,8 the risk estimate for death from cardiovas-
cular causes changes minimally, from 0.91 (95% 
CI, 0.84 to 0.99) to 0.94 (95% CI, 0.87 to 1.10).
In our study, the dose of n–3 fatty acids was 
not chosen on the basis of any estimate of its 
effect on triglyceride levels. Nevertheless, a sig-
nificant between-group difference in triglyceride 
levels was shown for patients receiving n–3 fatty 
acids (a reduction of 0.16 mmol per liter), which 
was in keeping with the triglyceride reduction 
shown in a similar study involving patients with 
diabetes, in which those receiving 2 g of n–3 
fatty acids per day had a reduction in the triglyc-
eride level of 0.09 mmol per liter.19 Although in 
our study other lipid values changed between 
baseline and the end of the study, the changes 
were similar in the two groups.
Among the strengths of our study are its 
large size, the large number of events, the long 
follow-up period, high adherence to study medi-
cation, ascertainment of the final outcome status 
in 99% of participants, and a focus on patients 
with diabetes or a glycemic status indicating a 
high risk of diabetes, a population in which n–3 
fatty acid supplementation has not been exten-
sively studied. Limitations of the study include the 
possibility that a daily dose of 1 g of n–3 fatty 
acids may have been too low. However, this dose 
was chosen on the basis of previous trials that 
showed a reduction in cardiovascular events.12 
Although the cardiovascular effect of daily doses 
ranging from 0.4 g to 4.8 g have been tested 
during the past 15 years, a recent meta-analysis8 
did not show a relationship between results and 
dose. Nevertheless, whether larger doses of n–3 
fatty acids can reduce cardiovascular events is 
unknown. Furthermore, assessment of whether 
the effect of n–3 fatty acids on death from car-
diovascular causes varied according to dietary 
intake of n–3 fatty acids was based on the use of 
a dietary questionnaire rather than measurement 
of serum levels.
At least three other large trials, currently un-
der way, are assessing the use of n–3 fatty acids 
to prevent cardiovascular disease in low-risk par-
ticipants. In the Rischio and Prevenzione study, 
Table 3. Changes in Key Risk Factors.*
Risk Factor
n–3 Fatty Acids
(N = 6281)
Placebo
(N = 6255) P Value
Blood pressure (mm Hg)
Systolic −4.37±22.5 −4.51±22.5 0.75
Diastolic −4.93±12.8 −4.96±13.1 0.91
Heart rate (beats/min) −0.13±12.3 0.25±12.2 0.13
Cholesterol (mg/dl)
Total −15.7±1.0 −14.6±1.0 0.17
Low-density lipoprotein −11.8±0.8 −12.4±0.8 0.44
High-density lipoprotein −0.1±0.3 −0.2±0.3 0.78
Triglycerides (mg/dl) −23.5±3.0 −9.0±3.0 <0.001
* Plus–minus values are means ±SD for blood pressure and heart rate and means 
±SE for cholesterol and triglycerides.
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among 12,513 participants who underwent ran-
domization between February 2004 and March 
2007, investigators are evaluating whether 5 years 
of daily supplementation with 1 g of n–3 fatty 
acids can prevent death or hospitalization for 
cardiovascular events in participants without 
previous myocardial infarction.20 Follow-up was 
completed in October 2011, and results are 
awaited. A Study of Cardiovascular Events in 
Diabetes (ASCEND, NCT00135226), involving 
15,480 participants with diabetes but no previ-
ous cardiovascular disease, is assessing wheth-
er daily supplementation with 1 g of n–3 fatty 
acids, as compared with placebo, will prevent 
cardiovascular events. Follow-up of participants 
will continue until 2017. The third large study, 
the Vitamin D and Omega-3 Trial (VITAL, 
NCT01169259), is currently recruiting 20,000 
participants in the United States who have no 
history of heart disease, stroke, or cancer to 
determine whether daily supplementation with 1 g 
of n–3 fatty acids will prevent these diseases. 
These studies will provide further evidence re-
garding the value of supplementation with n–3 
fatty acids. In addition, the three studies include 
both high- and low-risk participants and will 
therefore provide important information about 
the effect of supplementation with n–3 fatty ac-
ids in persons at various risk levels.
In conclusion, the administration of 1 g of 
n–3 fatty acids did not reduce the rate of death 
from cardiovascular causes or other outcomes 
during a period of 6 years in patients with dys-
glycemia and additional cardiovascular risk fac-
tors. Whether similar results would have been 
observed at higher doses is unknown. Further-
more, these findings may not be relevant to di-
etary recommendations to consume more fish, 
because dietary change not only increases the 
intake of foods containing n–3 fatty acids but is 
also associated with a reduction in the consump-
tion of foods such as red meats, which may be 
harmful.21
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BioPharma Norge.
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